<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000440</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAFAR11222</org_study_id>
    <nct_id>NCT00000440</nct_id>
  </id_info>
  <brief_title>Sertraline and Naltrexone for Alcohol Dependence</brief_title>
  <official_title>Sertraline and Naltrexone for Alcohol Dependents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</source>
  <brief_summary>
    <textblock>
      This study is a double-blind, placebo-controlled outpatient trial to improve, through the&#xD;
      addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent&#xD;
      individuals currently taking naltrexone (Revia).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date>September 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>124</enrollment>
  <condition>Alcoholism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone (Revia)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline (Zoloft)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets the criteria for alcohol dependence.&#xD;
&#xD;
          -  Abstinent from alcohol for a period of at least 5 days and not greater than 30 days.&#xD;
&#xD;
          -  Able to read English and complete study evaluations.&#xD;
&#xD;
          -  A stable residence and a telephone to ensure that subjects can be located during the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently meets criteria for substance abuse or dependence with the exception of&#xD;
             nicotine dependence.&#xD;
&#xD;
          -  Current use of disulfiram (Antabuse) or a MAO Inhibitor.&#xD;
&#xD;
          -  Psychotic or otherwise severely psychiatrically disabled (i.e., depressed, suicidal,&#xD;
             current mania).&#xD;
&#xD;
          -  Major depression at the time of assessment.&#xD;
&#xD;
          -  Previous treatment with naltrexone (Revia) for alcohol dependence.&#xD;
&#xD;
          -  Significant underlying medical conditions such as cerebral, renal, thyroid, or cardiac&#xD;
             disease.&#xD;
&#xD;
          -  Abstinent longer than 30 days prior to admission to program.&#xD;
&#xD;
          -  Hepatocellular disease or elevated bilirubin levels.&#xD;
&#xD;
          -  Females who are pregnant, nursing, or not using a reliable method of birth control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry, Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2004</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>November 2, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

